

## President's Page: Beijing 2009

Jay N. Cohn

Published online: 25 September 2009  
© Springer Science + Business Media, LLC 2009

The 15th biannual International Congress of the International Society of Cardiovascular Pharmacotherapy (ISCP) will be held on October 11–12, 2009 in Beijing in collaboration with the annual Great Wall International Congress of Cardiology.

An exciting structured program has been finalized covering a wide range of contemporary issues in drug therapy for cardiovascular diseases. A feature of the program will be the Henry Neufeld Memorial Lecture given this year by Juan Carlos Kaski, Vice-President of ISCP. Poster sessions of selected submitted abstracts will provide an opportunity for wider participation. Young Investigator Awards will be bestowed on those abstracts from young researchers selected for excellence by a review committee.

The program for the meeting is shown below.

Jay N. Cohn, M.D, President

---

J. N. Cohn (✉)  
Cardiovascular Division, Mayo Mail Code 508,  
University of Minnesota Medical School,  
420 Delaware Street Southeast,  
Minneapolis, MN 55455, USA  
e-mail: cohnx001@umn.edu

# THE 15<sup>TH</sup> INTERNATIONAL CONGRESS ON CARDIOVASCULAR PHARMACOTHERAPY

## *Program*

SUNDAY, OCTOBER 11, 2009

### **Drugs to Reduce Cardiovascular Risk**

**Co-chair: Jay N. Cohn**

**Co-chair: Zhu Junren**

- 8:00      Role of endothelium in vascular and cardiac injury  
            Paul Vanhoutte
- 8:20      Lipid lowering drugs for primary and secondary prevention  
            Rodolfo Paoletti
- 8:40      Anti-hypertensive therapy: Who is at risk and what is optimal therapy?  
            William Louis
- 9:00      Should high-risk patients receive anti-thrombotic therapy and which one?  
            Nicolas Danchin
- 9:20      Modern advances in anti-smoking therapy  
            John McNeil
- 9:40      *Neufeld Lecture*  
            Atheromatous plaque regression  
            Juan Carlos Kaski
- 10:15     Break

### **Joint ISCP-GWIIC Program**

**Co-chair: William Louis**

**Co-chair: Huo Yong**

- 10:45     CONSIDER – Survey on Cardiovascular Risk Factors in Hypertensive Patients in China  
            Zhao Dong
- 11:05     Management of hypertension: From hypertensive guidelines to clinical practice  
            Wang Jiguang
- 11:25     Statins: The cornerstone of anti-atherosclerosis treatment  
            Zhao Shuiping
- 11:45     Cholesterol management recommendations for hypertensive patients  
            Zhang Weizhong
- 12:05     Lunch

## Neurohormonal Inhibition in Cardiovascular Therapy

**Co-chair: Dennis Cokkinos**

**Co-chair: Yan Xiaowei**

- 1:30 The renin-angiotensin system  
Jay N. Cohn
- 1:50 Aldosterone inhibition and cardiovascular protection: More important than it once appeared  
Felipe Martinez
- 2:10 Which beta blocker is most effective in heart failure?  
Willem Remme

## Drug Treatment of Arrhythmias

- 2:30 Management of atrial fibrillation  
Gheorghe-Andrei Dan
- 2:50 Management of ventricular arrhythmias  
Ali Oto
- 3:10 Break

## Management of Acute conditions: Pharmacologic Strategies and New Drugs

**Co-chair: Gheorghe-Andrei Dan**

**Co-chair: Zhu Jun**

- 3:30 Acute coronary syndromes  
Nicolas Danchin
- 3:50 Acute heart failure  
Willem Remme
- 4:10 Medical therapy of acute ST-elevation MI  
Dennis Cokkinos
- 4:30 Adjourn

## **MONDAY, OCTOBER 12, 2009**

### **Restoring Health to the Heart and Vasculature**

**Co-chair: Daniel Duprez**

**Co-chair: Gao Runlin**

- 9:00 Is vascular stiffness a target for therapy?  
Daniel Duprez
- 9:20 Prevention and regression of myocardial remodeling  
Dennis Cokkinos
- 9:40 Drugs to relieve myocardial ischemia  
Alex Battler
- 10:00 Relative benefit of blood pressure reduction in reducing cardiovascular risk  
William Louis
- 10:20 Discussion
- 10:30 Break

### **Controversies in Cardiovascular Therapy I**

**Co-chair: Miran Kenda**

**Co-chair: Chen Yundai**

- 11:00 Is pharmacotherapy appropriate in the elderly?  
Miran Kenda
- 11:20 What is the best regimen for inhibiting the renin-angiotensin system?  
Felipe Martinez
- 11:40 Drug therapy vs. mechanical reperfusion in chronic stable angina  
Alex Battler
- 12:00 Lunch

### **Controversies in Cardiovascular Therapy II**

**Co-chair: Juan Carlos Kaski**

**Co-chair: Hu Dayi**

- 1:30 How to best identify candidates for pharmacoprevention  
Jay N. Cohn
- 1:50 Should aspirin be used for primary prevention?  
John McNeil

- 
- 2:10 Is HDL still a target for therapy?  
Rodolfo Paoletti
- 2:30 Secondary prevention of CAD with ACE inhibitors: Struggle between life and death of the endothelium  
Roberto Ferrari
- 2:50 Do oral anti-diabetic drugs reduce cardiovascular disease risk?  
Daniel Duprez
- 3:10 Do new antianginal drugs represent a therapeutic advance?  
Juan Carlos Kaski
- 3:30 Critical issues in the ACC/AHA secondary prevention guidelines  
Sidney Smith
- 3:50 Adjourn